{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:41:12Z","timestamp":1775198472574,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172263"],"award-info":[{"award-number":["82172263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070945"],"award-info":[{"award-number":["32070945"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470153"],"award-info":[{"award-number":["32470153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Respiratory syncytial virus (RSV) causes severe lung infections in infants and the elderly. The conserved central domain (CCD) of the RSV G protein is a key antigenic fragment for inducing protective antibodies. In this study, we used the hepatitis B surface antigen (HBsAg) as a platform to present this RSV G CCD fragment. Methods: We first sequenced and compared several HBsAg genotypes from clinical samples and selected one as an expression candidate for further development. The RSV G CCD was then inserted into the selected candidate to generate a recombinant expression construct. Subviral particles (SVPs) were produced using both CHO cells and yeast expression systems. Particle assembly was examined using electron microscopy. Finally, the safety and immunogenicity of the recombinant vaccine were evaluated in mice. Results: We successfully identified HBsAg38 as a potential recombinant vaccine expression candidate due to its abundant expression and secretion. The RSV G CCD fragment was inserted into the candidate and efficiently expressed in both CHO cells and yeast. The expressed protein was effectively secreted and formed uniform, spherical particles. The resulting vaccine candidate was safe for mice, causing no detectable weight loss or organ damage. Immunization with the recombinant SVPs elicited antibody responses against both HBsAg and the RSV G CCD. Upon intranasal RSV challenge, vaccinated mice exhibited markedly reduced RSV F protein and mRNA levels in lung tissues compared to PBS controls, with the yeast-derived SVP group showing the most pronounced reduction. Histopathological analysis further revealed that immunized mice had significantly less alveolar destruction and inflammatory cell infiltration than the control group, confirming that the vaccine conferred effective protection against RSV-induced lung pathology. Conclusions: We successfully developed a novel antigen-displaying HBsAg platform for generating vaccines targeting multiple pathogens. The RSV G CCD-expressing HBsAg induced a strong antibody response and provided effective protection against RSV infection. This platform offers a promising new approach for the development of next-generation vaccines.<\/jats:p>","DOI":"10.3390\/vaccines14040311","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:41:03Z","timestamp":1774878063000},"page":"311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Immunogenicity Evaluation of an RSV Recombinant Vaccine Displaying a Conserved Domain of RSV G"],"prefix":"10.3390","volume":"14","author":[{"given":"Jingjing","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junli","family":"Jia","sequence":"additional","affiliation":[{"name":"The Laboratory Center for Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-3973","authenticated-orcid":false,"given":"Huamin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Nanjing Medical University, Nanjing 211166, China"},{"name":"Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-024-01858-5","article-title":"Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Van Royen, T., Rossey, I., Sedeyn, K., Schepens, B., and Saelens, X. (2022). How RSV Proteins Join Forces to Overcome the Host Innate Immune Response. Viruses, 14.","DOI":"10.3390\/v14020419"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41541-022-00591-w","article-title":"RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses","volume":"7","author":"Su","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yu, D., Zhang, C., Qi, Y., Liu, Z., Yang, D., Zhao, N., Ke, Z., Lu, X., and Li, Y. (2025). RSV Vaccines: Targeting Prefusion F and G Proteins from Structural Design to Clinical Application. Vaccines, 13.","DOI":"10.3390\/vaccines13111133"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"1053","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"389","author":"Buonsenso","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for Prevention of RSV Disease in Healthy Infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1093\/cid\/ciaf061","article-title":"Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons","volume":"81","author":"Walsh","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Johnson, S.M., McNally, B.A., Ioannidis, I., Flano, E., Teng, M.N., Oomens, A.G., Walsh, E.E., and Peeples, M.E. (2015). Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005318"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jones, H.G., Ritschel, T., Pascual, G., Brakenhoff, J.P.J., Keogh, E., Furmanova-Hollenstein, P., Lanckacker, E., Wadia, J.S., Gilman, M.S.A., and Williamson, R.A. (2018). Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006935"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eaar3534","DOI":"10.1126\/sciimmunol.aar3534","article-title":"Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies","volume":"3","author":"Fedechkin","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Han, R., Wang, T., Cheng, X., Bing, J., Li, J., Deng, Y., Shan, X., Zhang, X., Wang, D., and Sun, S. (2024). Immune Responses and Protection Profiles in Mice Induced by Subunit Vaccine Candidates Based on the Extracellular Domain Antigen of Respiratory Syncytial Virus G Protein Combined with Different Adjuvants. Vaccines, 12.","DOI":"10.3390\/vaccines12060686"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1165\/rcmb.2013-0360OC","article-title":"Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection","volume":"51","author":"Han","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.1502103","article-title":"A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease","volume":"196","author":"Li","year":"2016","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14760584.2025.2508517","article-title":"Virus-like particles: A versatile and effective vaccine platform","volume":"24","author":"Bachmann","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ho, J.K., Jeevan-Raj, B., and Netter, H.J. (2020). Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses, 12.","DOI":"10.3390\/v12020126"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Garg, S., Ochetto, A., Hu, J., and Wang, J.C. (2024). Unveiling the Molecular Architecture of HBV Spherical Subviral Particles: Structure, Symmetry, and Lipid Dynamics. Viruses, 17.","DOI":"10.3390\/v17010048"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): An overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccine Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","article-title":"Feasibility, safety, and impact of the RTS,S\/AS01(E) malaria vaccine when implemented through national immunisation programmes: Evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi","volume":"403","author":"Asante","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pantazica, A.M., Dobrica, M.O., Lazar, C., Scurtu, C., Tucureanu, C., Caras, I., Ionescu, I., Costache, A., Onu, A., and Clarke, J.L. (2022). Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S\/preS1(16-42) antigen. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.941243"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1203\/00006450-199904020-01040","article-title":"A Novel Murine Model of Primary Respiratory Syncytial Virus (RSV) Infection","volume":"45","author":"Stack","year":"1999","journal-title":"Pediatr. Res."},{"key":"ref_30","first-page":"8431243","article-title":"Construction and Characterization of a Recombinant Human Respiratory Syncytial Virus Encoding Enhanced Green Fluorescence Protein for Antiviral Drug Screening Assay","volume":"2018","author":"Xu","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41467-024-44869-0","article-title":"Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds","volume":"15","author":"Wamhoff","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.01.012","article-title":"The impact of size on particle drainage dynamics and antibody response","volume":"331","author":"Zinkhan","year":"2021","journal-title":"J. Control Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1128\/JVI.00133-15","article-title":"Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels","volume":"89","author":"Fuentes","year":"2015","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Facciol\u00e0, A., Visalli, G., Lagan\u00e0, A., and Di Pietro, A. (2022). An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines, 10.","DOI":"10.3390\/vaccines10050819"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/bmj.38719.435833.7C","article-title":"Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and meta-analysis","volume":"332","author":"Lee","year":"2006","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bergeron, H.C., Murray, J., Juarez, M.G., Nangle, S.J., DuBois, R.M., and Tripp, R.A. (2023). Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1215323"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:31:22Z","timestamp":1775190682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["vaccines14040311"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14040311","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}